Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
SELLAS Life Sciences Group, Inc. (SLS) had Consolidated Net Income/Loss of $-6.60M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-6.60M |
|
-- |
|
-- |
|
$6.87M |
|
$-6.87M |
|
$0.27M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
|
Consolidated Net Income/Loss |
$-6.60M |
$-6.60M |
|
$-6.87M |
|
$-6.87M |
|
98.56M |
|
98.56M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$29.45M |
|
-- |
|
$2.86M |
|
$32.30M |
|
$6.00M |
|
-- |
|
$0.16M |
|
$6.16M |
|
$26.15M |
|
$24.23M |
|
$26.15M |
|
100.37M |
|
| Cash Flow Statement Financials | |
$-16.40M |
|
-- |
|
$27.81M |
|
$13.99M |
|
$25.40M |
|
$11.41M |
|
$1.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.91 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.40M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.24% |
|
-27.24% |
|
-20.43% |
|
-25.24% |
|
$0.26 |
|
$-0.17 |
|
$-0.17 |
|